Compare BELFA & BCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BELFA | BCRX |
|---|---|---|
| Founded | 1949 | 1986 |
| Country | United States | United States |
| Employees | 4964 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.1B |
| IPO Year | N/A | 1995 |
| Metric | BELFA | BCRX |
|---|---|---|
| Price | $193.19 | $9.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $20.82 |
| AVG Volume (30 Days) | 53.7K | ★ 6.3M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.12% | N/A |
| EPS Growth | N/A | ★ 381.40 |
| EPS | N/A | ★ 1.21 |
| Revenue | N/A | ★ $25,186,000.00 |
| Revenue This Year | $28.52 | N/A |
| Revenue Next Year | $7.85 | $12.55 |
| P/E Ratio | $40.02 | ★ $7.76 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $53.95 | $6.00 |
| 52 Week High | $227.42 | $11.31 |
| Indicator | BELFA | BCRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.54 | 65.87 |
| Support Level | $114.22 | $7.85 |
| Resistance Level | $227.42 | N/A |
| Average True Range (ATR) | 8.94 | 0.57 |
| MACD | 1.53 | 0.02 |
| Stochastic Oscillator | 62.13 | 63.13 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
BioCryst Pharmaceuticals Inc is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, to block key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modeling, and medicinal chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.